Search Results - oncology

219 Results Sort By:
Stratification Method that Determines the Prognosis of Breast Cancer at a Personalized Level
A reliable, accurate, and versatile method for determining the prognosis of primary breast cancer tumors post-surgery. Background: Breast cancer is the second most common type of cancer in women in the United States, after skin cancer. On rare occasions, it can also occur in men. According to the American Cancer Society, nearly 300,000 new cases...
Published: 4/1/2025   |   Inventor(s): Vladimir Kuznetsov, Leszek Kotula
Keywords(s): biomarkers, biostatistics, breast cancer, diagnostics, functional genomics, gene expression analysis, oncology, Technologies
Category(s): Campus > Upstate Medical University, Technology Classifications > Biomedical Science and Engineering, Technology Classifications > Diagnostics, Technology Classifications > Healthcare, Technology Classifications > Medical Devices
Brain Cancer: Novel Prognostic Method and Therapeutic Target for Glioblastoma
Advantages: A precision-guided method for identifying glioblastoma-related genes that improves assessment of the current prognostic biomarker Enables the identification of potential novel therapeutic targets: GLP1R agonists, which are already used for managing obesity and type 2 diabetes, could be explored as treatments for GBM Broader Applications:...
Published: 3/24/2025   |   Inventor(s): George Blanck, Teresa Thomas
Keywords(s): Cancer Diagnostics, Medical Diagnostics, Oncology, Therapeutics
Category(s): Technology Classifications > Cancer > Cancer Diagnostics, Technology Classifications > Medical > Medical Diagnostics, Technology Classifications > Medical > Oncology, Technology Classifications > Medical > Therapeutics
Anticancer IgG Against Multiple Epitopes on Live Tumors Upon Disruption of ‘Self’ Signaling by CD47
A method to combine two or three monoclonal antibodies (mABs) into one treatment to successfully bind to multiple cancer cell surface epitopes and promote targeted degradation by phagocytosis. Problem: Phagocytosis of ‘self’ cells is generally inhibited by a key macrophage checkpoint interaction between SIRPα on the macrophage and...
Published: 2/27/2025   |   Inventor(s): Dennis Discher, Jason Andrechak, Lawrence Dooling
Keywords(s): Antibody, Bioengineering, Cell Therapy, Drug Target, Immunology, Immunoncology, Immunotherapy, Oncology, Platform Technology
Category(s): Technology Classifications > Therapeutics
T-Cell-Activating Lipid Nanoparticles for Rapid Engineering of CAR T Cells
A method to streamline the process of generating chimeric antigen receptor (CAR) T cells for therapeutic applications. Problem: CAR T cell therapy has demonstrated clinical success in treating various forms of cancer. With more CAR T cell therapies projected to gain regulatory approval, manufacturing becomes increasingly important in the face of this...
Published: 12/20/2024   |   Inventor(s): Ann Metzloff, Margaret Billingsley, Michael Mitchell
Keywords(s): Bioengineering, Cell Therapy, Drug Delivery, Immunoncology, Immunotherapy, Oncology, Platform Technology
Category(s): Technology Classifications > Therapeutics
Prodrug Lipid Nanoparticles for Synergistic Cancer Immunotherapy
Prodrug lipid nanoparticle (LNP) with a mRNA encoding for a therapeutic cytokine for solid tumor immunotherapy.</brief> Problem: Approximately 2 million people are diagnosed with cancer each year in the United States. Messenger RNA (mRNA)-based cancer immunotherapy has emerged as a potential cancer treatment using cytotoxic T cells to eliminate...
Published: 1/7/2025   |   Inventor(s): Michael Mitchell, Qiangqiang Shi
Keywords(s): Bioengineering, Drug Delivery, Oncology, Platform Technology
Category(s): Technology Classifications > Therapeutics
Method to Alleviate Side Effects of CAR T Cell Immunotherapies
CAR-T cells are PEGylated to block the interactions with monocytes and macrophages to reduce the side effects of CAR-T cell therapies (cytokine release syndrome and neurotoxicity). Problem: CAR-T cell therapies lead to many adverse side effects such as cytokine release syndrome (CRS) and neurotoxicity. It has been shown that 20-70% of patients receiving...
Published: 12/20/2024   |   Inventor(s): Michael Mitchell, Ningqiang Gong
Keywords(s): Bioengineering, Cell Therapy, Immunology, Immunoncology, Immunotherapy, Oncology
Category(s): Technology Classifications > Chemical Processes and Synthesis, Technology Classifications > Therapeutics
Novel RNA Binding Protein Targets to Treat Melanoma
Figure 1. RNA-binding proteins as novel oncological targets. (A) Unbiased screen on cell lines with increasing cancer aggressiveness​. (B) Specific inhibition of the RNA binding domain of one of the hit candidate RBPs affects tumoral cells viability. Novel antitumoral RNA-binding protein targets in melanoma identified by an unbiased screen. We are...
Published: 10/28/2024   |   Inventor(s): Fatima Gebauer, Neus Mestre Farras, Santiago Guerrero
Keywords(s): Melanoma, Oncology
Category(s): Drug Targets & Mechanisms, Therapeutics (Biologics & Compounds)
NudTx: Targeting Cancer Stem Cells
Small molecules hits, and companion diagnostic, selective for the ATP generating activity of NUDT5. We are developing lead compounds that eventually could be used to complement poly ADP-ribose polymerase therapy or as a treatment on itself as an alternative treatment option to treat primary and metastatic cancers. Technology: Recurrence and metastasis...
Published: 10/4/2024   |   Inventor(s): Miguel Beato, Roni Wright
Keywords(s): Metastasis, Oncology
Category(s): Drug Targets & Mechanisms, Therapeutics (Biologics & Compounds)
Novel Therapeutic Targets for DIPG
Various antitumoral targets identified from an unbiased multiomics screen on H3K27M mutated Diffuse Midline Glioma patient-derived material. We are finalizing target validation and developing high throughput small molecule screening assays to develop novel compounds that can be used to treat this devastating childhood cancer. Technology: Diffuse...
Published: 11/21/2024   |   Inventor(s): Luciano Di Croce, Maria Espejo Diaz
Keywords(s): Epigenetics, Oncology, Paediatric Disease
Category(s): Drug Targets & Mechanisms, Therapeutics (Biologics & Compounds)
Inhibitors of the N-terminal Domain of the Androgen Receptor (UCLA Case No. 2023-075)
Researchers at UCLA under the guidance of Drs. Matthew Rettig and Michael Jung have developed novel molecular compounds that reduce growth of prostate cancer cells. Dr. Jung in collaboration with Dr. Rettig have furthered the development of these compounds by synthesizing a new series of analogues that have similar inhibitory effects. BACKGROUND: Prostate...
Published: 2/14/2025   |   Inventor(s): Matthew Rettig, Michael Jung
Keywords(s): androgen receptor therapy, castration resistant prostate cancer, Oncology, Oncology (Small Molecules, Peptides and Antibodies), prostate cancer, small molecules
Category(s): Therapeutics > Oncology, Therapeutics > Oncology > Oncology (Small Molecules)
1 2 3 4 5 6 7 8 9 10 ...